A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
← catalyst calendarNCT05952037 · readout in 34 d
Sponsored by BeOne Medicines (industry) · ONC — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
114actual
Sites
72
Countries
Australia, Canada, China +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-23 | actual | When the study began enrolling |
| Primary completion | 2026-09-22 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2023-07-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Waldenstrom Macroglobulinemia
- Waldenstrom's Macroglobulinemia Recurrent
- Waldenstrom's Macroglobulinemia Refractory
Interventions
- Drug: Sonrotoclax — also filed as BGB-11417
- Drug: Zanubrutinib — also filed as BRUKINSA, BGB-3111
Primary outcome
what the primary-completion date above is the date OFCohort 1: Major Response Rate (MRR)
measured Up to approximately 4 years
Permalink · ONC's whole pipeline · Catalyst calendar · Every registered study · What changed